False resistance after artemether–lumefantrine treatment in a falciparum malaria patient in Turkey: A case report

Artemisinin-based combination therapy (ACT) is recommended by the World Health Organization as first-line treatment of uncomplicated Plasmodium falciparum malaria. ACT treatments failures among travellers returning from Africa to non-endemic countries are considered to be caused by resistance. We re...

Full description

Saved in:
Bibliographic Details
Published inIDCases Vol. 18; p. e00607
Main Authors Koru, Ozgur, Yazici, Ertugrul, Rasmussen, Charlotte, Ringwald, Pascal, Artuk, Cumhur, Bedir, Orhan
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.01.2019
Elsevier
Subjects
Artemisinin-based combination therapy
Malaria
P. falciparum
Malaria
Artemisinin-based combination therapy
P. falciparum
Online AccessGet full text

Cover

More Information
Summary:Artemisinin-based combination therapy (ACT) is recommended by the World Health Organization as first-line treatment of uncomplicated Plasmodium falciparum malaria. ACT treatments failures among travellers returning from Africa to non-endemic countries are considered to be caused by resistance. We report on a case of artemether-lumefantrine treatment failure in a Turkish traveller with uncomplicated P. falciparum malaria returning from Bamako, Mali. Information on returning travellers, includes ensuring that the patients receive supervised treatment with the recommended dose of a quality controlled medicine, routine follow-up of all cases, assessment of adequate absorption of the drug, and/or testing the prevalence of molecular markers of drug resistance if validated, can be an important source of an early warning system for emerging resistance.
ISSN:2214-2509
2214-2509
DOI:10.1016/j.idcr.2019.e00607